ArticleBMC psychiatry2026
Diagnosis-specific associations of plasma NGAL in drug-naïve schizophrenia and major depressive disorder: an exploratory cross-sectional study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSchizophrenia (SCZ) and major depressive disorder (MDD) share overlapping clinical features. We examined plasma neutrophil gelatinase-associated lipocalin (NGAL) in drug-naïve patients to investigate differences between diagnostic groups and their associations with clinical symptoms and cognitive performance.
methodsWe recruited 510 participants (246 with SCZ, 158 with MDD, and 106 healthy controls [HC]) from 2017 to 2025. Plasma NGAL was measured using ELISA. Cognition was assessed with MCCB (SCZ) and RBANS (MDD). We employed partial correlations and multiple linear regression (FDR-corrected) to examine NGAL-clinical and cognitive associations. Receiver operating characteristic (ROC) curves with five-fold cross-validation were used to evaluate diagnostic discrimination.
resultsPlasma NGAL levels differed significantly across groups (P < 0.001): levels were highest in MDD, lowest in SCZ, with HC intermediate. Following Box-Cox transformation, partial Pearson correlation revealed that in SCZ, NGAL correlated consistently and negatively with core symptoms (Positive: r = -0.289, P < 0.001; Negative: r = -0.138, P = 0.005), while remaining positively associated with general psychopathology (r = 0.185, P = 0.005) and cognitive domains. Ten-times repeated five-fold cross-validation demonstrated high discriminative utility for NGAL: the highest accuracy was achieved in distinguishing SCZ from MDD (AUC = 0.857), followed by SCZ versus others (AUC = 0.826) and MDD versus others (AUC = 0.805).
conclusionsOur findings demonstrate a distinctive bidirectional profile in plasma NGAL levels, where elevations in MDD and reductions in SCZ reflect divergent immune dysregulation signatures at the early stages of these disorders. Within the Immune Response System (IRS)–Compensatory Immune-regulatory System (CIRS) framework, these results suggest a failure of compensatory neuroprotective mechanisms in SCZ compared to persistent inflammatory activation in MDD. Collectively, NGAL serves as a promising biological adjunct to enhance the objective differentiation between SCZ and MDD, though longitudinal studies are warranted to validate its predictive value across illness trajectories.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.